A Phase 1/Phase 2 Trial to Evaluate Safety, Immunogenicity and PSA Response of VTP-850 Prostate Cancer Immunotherapeutic in Men With Biochemical Recurrence After Definitive Local Therapy for Prostate Cancer
Latest Information Update: 26 Sep 2025
At a glance
Most Recent Events
- 07 Aug 2025 According to Barinthus Biotherapeutics media release, this trial is now complete, with no treatment related SAEs reported. Data shows encouraging signs of immunogenicity and will be used to facilitate partnering discussions.
- 07 May 2025 According to Barinthus Biotherapeutics media release, topline results from this study were received and analysis is ongoing.
- 10 Jan 2025 According to Barinthus Biotherapeutics media release, results from this trial are expected in Q2 2025.